CN108420994B - 一种用于治疗癫痫抽搐、小儿惊风、面肌痉挛的药物组合物及其制备方法 - Google Patents
一种用于治疗癫痫抽搐、小儿惊风、面肌痉挛的药物组合物及其制备方法 Download PDFInfo
- Publication number
- CN108420994B CN108420994B CN201810382701.4A CN201810382701A CN108420994B CN 108420994 B CN108420994 B CN 108420994B CN 201810382701 A CN201810382701 A CN 201810382701A CN 108420994 B CN108420994 B CN 108420994B
- Authority
- CN
- China
- Prior art keywords
- parts
- extract
- radix
- medicinal
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010010904 Convulsion Diseases 0.000 title claims abstract description 17
- 230000036461 convulsion Effects 0.000 title claims abstract description 16
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 16
- 206010063006 Facial spasm Diseases 0.000 title claims abstract description 7
- 238000002360 preparation method Methods 0.000 title claims description 21
- 239000000463 material Substances 0.000 claims abstract description 64
- 239000002775 capsule Substances 0.000 claims abstract description 48
- 239000000284 extract Substances 0.000 claims abstract description 42
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims abstract description 34
- 239000000843 powder Substances 0.000 claims abstract description 32
- 229910000019 calcium carbonate Inorganic materials 0.000 claims abstract description 17
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000011575 calcium Substances 0.000 claims abstract description 11
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 11
- 210000000941 bile Anatomy 0.000 claims abstract description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- 238000002156 mixing Methods 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 12
- 241000255789 Bombyx mori Species 0.000 claims description 10
- 238000001035 drying Methods 0.000 claims description 9
- 239000002671 adjuvant Substances 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 235000006533 astragalus Nutrition 0.000 claims description 7
- 241000489492 Arisaema Species 0.000 claims description 5
- 241000007126 Codonopsis pilosula Species 0.000 claims description 5
- 241000305491 Gastrodia elata Species 0.000 claims description 5
- 244000303040 Glycyrrhiza glabra Species 0.000 claims description 5
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 5
- 241001080798 Polygala tenuifolia Species 0.000 claims description 5
- 241000304195 Salvia miltiorrhiza Species 0.000 claims description 5
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 claims description 5
- 241000157352 Uncaria Species 0.000 claims description 5
- 239000000706 filtrate Substances 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 5
- 235000011477 liquorice Nutrition 0.000 claims description 5
- 238000007873 sieving Methods 0.000 claims description 5
- 241000382455 Angelica sinensis Species 0.000 claims description 4
- 241000045403 Astragalus propinquus Species 0.000 claims description 4
- 239000000203 mixture Substances 0.000 abstract description 14
- 238000011049 filling Methods 0.000 abstract description 7
- 238000005429 filling process Methods 0.000 abstract description 5
- 230000007774 longterm Effects 0.000 abstract description 4
- 241000255791 Bombyx Species 0.000 abstract description 3
- 239000010271 massa medicata fermentata Substances 0.000 abstract description 3
- 241000756943 Codonopsis Species 0.000 abstract description 2
- 239000009636 Huang Qi Substances 0.000 abstract description 2
- 210000000582 semen Anatomy 0.000 abstract description 2
- 239000003814 drug Substances 0.000 description 33
- 206010015037 epilepsy Diseases 0.000 description 25
- 238000010521 absorption reaction Methods 0.000 description 15
- 229940079593 drug Drugs 0.000 description 14
- 238000011160 research Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 206010062717 Increased upper airway secretion Diseases 0.000 description 7
- 208000026435 phlegm Diseases 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 238000009825 accumulation Methods 0.000 description 6
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 6
- 235000019700 dicalcium phosphate Nutrition 0.000 description 6
- 238000005303 weighing Methods 0.000 description 6
- 239000008187 granular material Substances 0.000 description 5
- 238000005469 granulation Methods 0.000 description 5
- 230000003179 granulation Effects 0.000 description 5
- 230000035876 healing Effects 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- 241001061264 Astragalus Species 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 210000004233 talus Anatomy 0.000 description 3
- 210000001835 viscera Anatomy 0.000 description 3
- IBGBGRVKPALMCQ-UHFFFAOYSA-N 3,4-dihydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1O IBGBGRVKPALMCQ-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 239000001961 anticonvulsive agent Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 238000003892 spreading Methods 0.000 description 2
- 230000007480 spreading Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 241000125175 Angelica Species 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 235000001287 Guettarda speciosa Nutrition 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- QMNWISYXSJWHRY-YLNUDOOFSA-N astragaloside IV Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)[C@H]4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)C[C@H]3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-YLNUDOOFSA-N 0.000 description 1
- QMNWISYXSJWHRY-BCBPIKMJSA-N astragaloside IV Natural products CC(C)(O)[C@@H]1CC[C@@](C)(O1)[C@H]2[C@@H](O)C[C@@]3(C)[C@@H]4C[C@H](O[C@@H]5O[C@H](CO)[C@H](O)[C@@H](O)[C@H]5O)[C@H]6C(C)(C)[C@H](CC[C@@]67C[C@@]47CC[C@]23C)O[C@@H]8OC[C@@H](O)[C@H](O)[C@H]8O QMNWISYXSJWHRY-BCBPIKMJSA-N 0.000 description 1
- 229940107666 astragalus root Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- PFKIBRPYVNVMRU-UHFFFAOYSA-N cyclosieversioside F Natural products CC(C)(O)C1COC(C)(C1)C2C(O)CC3(C)C4CC(OC5OC(CO)C(O)C(O)C5O)C6C(C)(C)C(CCC67CC47CCC23C)OC8OCC(O)C(O)C8O PFKIBRPYVNVMRU-UHFFFAOYSA-N 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000001037 epileptic effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 238000010304 firing Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 238000013386 optimize process Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229960003371 protocatechualdehyde Drugs 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/233—Bupleurum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/69—Polygalaceae (Milkwort family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A61K36/725—Ziziphus, e.g. jujube
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
- A61K36/8884—Arisaema, e.g. Jack in the pulpit
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8988—Gastrodia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Insects & Arthropods (AREA)
- Inorganic Chemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明提供一种用于治疗癫痫抽搐、小儿惊风、面肌痉挛的药物组合物,包括药材提取物和辅料;所述辅料选自碳酸钙和磷酸氢钙中的一种或两种,以所述药材提取物的重量为基准,所述辅料的重量百分比为10%;所述药材提取物由如下中药材经过提取制备得到:黄芪、党参、丹参、柴胡、酸枣仁、远志、天麻、钩藤、石菖蒲、胆南星、当归、僵蚕、六神曲、郁金、甘草、制白附子。本发明提供的药物组合物流动均匀流畅,在制备成胶囊剂时粘附粉冲杆情况明显改善,从而使得填充过程稳定,填充后的胶囊装量差异范围小,胶囊剂的长期稳定性更好。
Description
技术领域
本发明涉及中药制剂技术领域,具体涉及一种用于治疗癫痫抽搐、小儿惊风、面肌痉挛的药物组合物及其制备方法,更具体的,所述药物是痫愈胶囊。
背景技术
癫痫,又称为“羊角风”,是由大脑神经元异常放电,导致短暂的中枢神经系统功能失常为特征的慢性脑部疾病。据中国最新流行病学资料显示,国内癫痫的总体患病率为7.0‰,年发病率为28.8/10万,1年内有发作的活动性癫痫患病率为4.6‰。据此估计中国约有900万左右的癫痫患者,其中500~600万是活动性癫痫患者,同时每年新增加癫痫患者约40万,在中国癫痫已经成为神经科仅次于头痛的第二大常见病。
目前国内外对于癫痫的治疗主要以药物治疗为主。癫痫患者经过正规的抗癫痫药物治疗,约70%的患者其发作是可以得到控制的,其中50%~60%的患者经过2~5年的治疗是可以痊愈的,患者可以和正常人一样地工作和生活。因此,合理、正规的抗癫痫药物治疗是关键。
癫痫病《素问》称为巅疾,即病变部位在巅顶(即脑部)。中医认为其病因病机可概括为痰、火、惊、气、血和先天因素几个方面,总不离惊恐、积痰、火郁,而其中尤以积痰为主要。正如叶天士《临证指南医案·癫痫门》按语所云“痫症或由惊恐,或由饮食不节,或由母腹中受惊,以致脏气不平,经久失调,一触积痰,厥气内风,卒焉暴逆,莫能禁止,待其气反然后已。”另外,由于癫痫多是时发时止,且呈反复发作,日久必然影响到五脏的功能,导致五脏气血阴阳俱虚,即所谓“痫久必归五脏”,故多见虚实夹杂、正虚邪实的情况。因此,中医治疗癫痫一般以祛痰、息风、定惊为主要治则,同时兼顾病因病机的其它方面。
痫愈胶囊是国家批准上市的治疗癫痫的成药(标准编号:WS-10525(ZD-0525)-2002-2012Z,国药准字Z20025728),处方为:黄芪140g、党参140g、丹参140g、柴胡70g、酸枣仁105g、远志70g、天麻105g、钩藤105g、石菖蒲70g、胆南星70g、当归140g、僵蚕105g、六神曲70g、郁金70g、甘草70g、制白附子35g,制成1000粒;具有豁痰开窍,安神定惊,息风解痉的功效,用于风痰闭阻所致的癫痫抽搐、小儿惊风、面肌痉挛。
现有工艺生产的痫愈胶囊现有制备工艺为:僵蚕、六神曲粉碎成细粉,过筛,备用;其余黄芪等十四味加水煎煮三次,第一次加水10倍量煎煮2小时,第二次加水8倍量煎煮次1.5小时,第三次加水6倍量煎煮1小时,合并煎液,滤过,滤液减压浓缩至相对密度为1.36(60℃)的稠膏,加入上述细粉,混合均匀,真空干燥,粉碎成细粉,湿法制粒,在70℃干燥,装入胶囊,制成1000粒,即得。
在生产实践中发现,按照上述制备方法,制粒后装胶囊过程中存在细颗粒易吸湿粘附粉冲杆,造成装量差异及频繁停机清理;而且制备得到的胶囊,在长期放置过程中存在胶囊内容物吸湿和积聚等问题。
发明内容
针对上述问题,通过处方研究、辅料筛选、工艺研究、产品小试,以及原工艺与优化后工艺大生产稳定性样品的对比研究;最终,发明人在中医理论的指导下,结合《已上市中药生产工艺变更研究技术指导原则》设计了所述痫愈胶囊的新的制剂处方并提出了所述痫愈胶囊的新的制备方法。按照新的制剂处方及制备方法制备得到的药粉在填充过程调机时间短,物料流动均匀流畅,粘附粉冲杆情况明显改善,从而使得填充过程稳定,填充后的胶囊装量差异范围小。另外,人员工时、机器工时均较现有技术有所减少。后续稳定性考察发现,本发明制备的痫愈胶囊稳定好,没有出现胶囊内容物吸湿和积聚等问题。
为了实现上述技术效果,本发明采用了如下的技术方案:
一种用于治疗癫痫抽搐、小儿惊风、面肌痉挛的药物组合物,包括药材提取物和辅料;所述辅料选自碳酸钙和磷酸氢钙中的一种或两种,以所述药材提取物的重量为基准,所述辅料的重量百分比为10%;所述药材提取物由如下中药材经过提取制备得到:
黄芪、党参、丹参、柴胡、酸枣仁、远志、天麻、钩藤、石菖蒲、胆南星、当归、僵蚕、六神曲、郁金、甘草、制白附子。
优选的,所述辅料碳酸钙和磷酸氢钙,碳酸钙和磷酸氢钙的重量比为1:1。
优选的,所述中药材的重量份为:
黄芪140重量份、党参140重量份、丹参140重量份、柴胡70重量份、酸枣仁105重量份、远志70重量份、天麻105重量份、钩藤105重量份、石菖蒲70重量份、胆南星70重量份、当归140重量份、僵蚕105重量份、六神曲70重量份、郁金70重量份、甘草70重量份、制白附子35重量份。
优选的,所述药材提物物通过如下方法制备:
按照重量份准备各味药材;僵蚕、六神曲粉碎成细粉,过80~100目筛,备用;其余十四味药材加水煎煮三次,第一次加水10倍量煎煮2小时,第二次加水8倍量煎煮次1.5小时,第三次加水6倍量煎煮1小时,合并煎液,滤过,滤液减压浓缩至相对密度为1.36(60℃)的稠膏,加入所述细粉,混合均匀,干燥,即得。
优选的,所述药物组合物为胶囊剂,胶囊内容物为所述药材提取物和所述辅料。
本发明还有一个目的在于提供上述胶囊剂的制备方法,包括如下步骤:
I.将所述药材提取物粉碎,过80~100目筛,得到提取物细粉,备用;
II.将所述辅料粉碎(如有必要),混合均匀;然后与步骤I得到的提取物细粉混合均匀;
III.向步骤II得到的混合细粉中适量乙醇,制粒,干燥,装胶囊,即得。
优选的,所述乙醇为体积百分比浓度80%~85%的乙醇水溶液。
在本说明书中,如果没有明确地规定,一个数值点,不仅仅包括该数值本身,还包括这个数值±10%,优选±7%,更优选±5%范围内的所有数值。例如,上文所述“以所述药材提取物的重量为基准,所述辅料的重量百分比为10%”,即是指所述辅料的重量为所述药材提取物的重量的9%~11%,优选为9.3%~10.7%,更优选为9.5%~10.5%。
本说明书中,所述重量份数不是所述各味药材的实际重量,“重量份”也不是一个实际的重量单位;重量份数表示的是各味药材之间的重量配比关系。根据实际情况,1重量份可以是1kg,或者1g,或者1斤(500g),或者10g(如实施例1所示的情形),等等。
本发明提供的药物组合物及胶囊剂的制备方法不仅解决了现有技术中存在的痫愈胶囊制剂过程中存在的困难,大大节约了生产成本,提高了生产效率,而且胶囊剂的稳定性均优于现有技术的痫愈胶囊剂,没有出现胶囊内容物吸湿和积聚等问题。
具体实施方式
以下参照具体的实施例来说明本发明。本领域技术人员能够理解,这些实施例仅用于说明本发明,其不以任何方式限制本发明的范围。
下述实施例中的实验方法,如无特殊说明,均为常规方法。下述实施例中所用的药材、辅料、试剂材料等,如无特殊说明,均为市售购买产品。
实施例1药材提物的制备
本实施例的所述药材提物,通过如下步骤制备:
1.取黄芪1400g(此处,1重量份=10g,下同)、党参1400g、丹参1400g、柴胡700g、酸枣仁1050g、远志700g、天麻1050g、钩藤1050g、石菖蒲700g、胆南星700g、当归1400g、僵蚕1050g、六神曲700g、郁金700g、甘草700g、制白附子350g。
2.将僵蚕、六神曲粉碎成细粉,过80~100目筛,备用;
3.取其余黄芪等十四味药材加水煎煮三次,第一次加水10倍量煎煮2小时,第二次加水8倍量煎煮次1.5小时,第三次加水6倍量煎煮1小时,合并煎液,滤过,滤液减压浓缩至相对密度为1.36(60℃)的稠膏,加入步骤2制备得到的所述细粉,混合均匀,真空干燥,粉碎,过筛,即得。
实施例2所述药物组合物中辅料种类的筛选试验
取实施例1制备的药物提取物50g,平均分为6份,分别加入相同重量(5g)的可溶性淀粉、微晶纤维素、碳酸钙、磷酸氢钙、乳糖、原药粉(僵蚕和六神曲按照10.5:7的比例混合,粉碎,过筛),分别记为1#(可溶性淀粉),2#(微晶纤维素),3#(碳酸钙),4#(磷酸氢钙),5#(乳糖),6#(原药粉),混合均匀,分别精密称取2g平摊于干燥至恒重的扁形称量瓶中,然后放置于底部盛有氯化钠过饱和溶液的玻璃干燥器中,在0,4,8,12,24,36,48,72,96h精密称重;每种辅料平行做3份,按照公式A计算吸湿百分率%,取平均值。结果见表1。
吸湿率%=(吸湿后重量-吸湿前重量)/吸湿前重量×100%A
表1不同辅料的药物组合物吸湿百分率的测定结果(%,n=3)
结果表明:相同的药物提物与不同辅料配伍后,得到的药物组合物吸湿性有显著的差异,吸湿率大小的排列顺序为:磷酸氢钙<碳酸钙<乳糖<微晶纤维素<可溶性淀粉<原药粉。因此初步选择磷酸氢钙、碳酸钙作为辅料,进行下一步的研究。另外,原药粉的吸湿率最大,显然现有技术以原药粉作为制剂辅料是合适的。
实施例3辅料用量比例筛选试验
取实施例1制备的药物提取物8份(每份40g),按照表2所示加入不同重量比例的碳酸钙和/或磷酸氢钙,混合均匀,分别精密称取2g平摊于干燥至恒重的扁形称量瓶中,防止于底部盛有氯化钠过饱和溶液的玻璃干燥器中放置24h,取出,再次精密称重;每种比例辅料平行做3份,按照公式A计算吸湿百分率%,取均值。结果见表2。
表2辅料配比/用量筛选试验结果
a:所述比例是指占所述药物提取物的重量百分比。
表2的结果显示:
1)组合物的吸湿率与辅料的用量明显相关,辅料总用量为10%时,组合物的吸湿率显著低于辅料用量为5%的组合物。
2)在辅料总用量相同的情况下,碳酸钙和磷酸氢钙等量合用时,组合物的吸湿率最小。
因此,优选辅料用量是所述药物提取物重量的10%,所述辅料选自碳酸钙和磷酸氢钙中的一种或两种。
更优选的,所述辅料的用量是所述药物提取物重量的10%,所述辅料由碳酸钙和磷酸氢钙组成。
最优选的,所述辅料的用量是所述药物提取物重量的10%,所述辅料由重量比为1:1的碳酸钙和磷酸氢钙组成。
实施例4制粒所用乙醇水溶液的体积百分比浓度的筛选试验
取实施例1制备的所述药物提取物5000g,加入碳酸钙、磷酸氢钙各5%(以所述药物提取物的重量为基准),混合均匀,平均分为4份,分别以体积百分比浓度75%、80%、85%、90%的乙醇水溶液制粒(每份用350ml),过20目筛,填充于自动胶囊机,观察填充下料情况、测定装量差异。结果见表3。
表3润湿剂的确定
b:乙醇浓度,即乙醇水溶液中乙醇的体积百分比浓度。
表3的结果显示:采用体积百分比75%的乙醇水溶液制粒,颗粒较多,下料不易控制,装量差异较大。采用体积百分比90%的乙醇水溶液制粒,细粉较多,药粉轻,下料困难,装量差异较大。采用体积百分比80%-85%的乙醇水溶液制粒,下料正常,装量差异小,因此,优选以体积百分比80%-85%的乙醇水溶液制粒。
实施例5本发明所述药物组合物胶囊剂的制备
黄芪140g、党参140g、丹参140g、柴胡70g、酸枣仁105g、远志70g、天麻105g、钩藤105g、石菖蒲70g、胆南星70g、当归140g、僵蚕105g、六神曲70g、郁金70g、甘草70g、制白附子35g,僵蚕、六神曲粉碎成细粉,过筛,备用;其余黄芪等十四味加水煎煮三次,第一次加水10倍量煎煮2小时,第二次加水8倍量煎煮次1.5小时,第三次加水6倍量煎煮1小时,合并煎液,滤过,滤液减压浓缩至相对密度为1.10~1.36(60℃)的稠膏,加入上述细粉,混合均匀,真空干燥,粉碎成细粉,共制备得到440g药物提物的细粉,与碳酸钙22g、磷酸氢钙22g混匀,用80%~85%乙醇适量制粒,在70~80℃干燥,装入胶囊,制成1000粒,即得。
重复操作3次,得到的胶囊剂分别记为20170305、20170306、20170307。
实施例6本发明所述药物胶囊剂的质量检测
仪器:
戴安Ultimate3000高效液相色谱仪系统及紫外检测器,安捷伦C18色谱柱(5μ,4.6×250mm)、UV-8三用紫外分析仪、水浴锅、烘箱、分析天平、崩解仪、干燥器、净化工作台、高压灭菌锅、培养箱等。
试剂:
三氯甲烷、正丁醇、氢氧化钠、乙醇、盐酸、乙酸乙酯、甲酸、三氯化铁、乙酸铵、冰醋酸、甲醇。
对照品:
黄芪甲苷:中国食品药品检定研究院110781-200613,供含量测定用。
原儿茶醛:中国食品药品检定研究院110810-200506,供含量测定用。
测试样品:
(1)现有技术的痫愈胶囊:按照药品标准WS-10525(ZD-0525)-2002-2012Z制备的三批胶囊,批号分别为20170302、20170303、20170304。
(2)实施例5制备的胶囊剂:批号分别为20170305、20170306、20170307。
试验方法:
按照痫愈胶囊质量标准WS-10525(ZD-0525)-2002-2012Z进行检测。
所有测试样品在相同条件下的0月及加速稳定性1个月、2个月、3个月、6个月,长期稳定性3个月、6个月的稳定测定结果分别见表4、表5、表6、表7、表8、表9、表10。
在0月及稳定性研究的各检测时间点,本发明提供的胶囊剂三批样品的装样差异范围都比现有技术的痫愈胶囊小。加速稳定性研究和长期稳定性研究结果均显示,现有技术的痫愈胶囊和本发明提供的胶囊剂三批样品各项检测数据虽然均符合痫愈胶囊的质量标准要求,但是在存放过程中,本发明提供的胶囊剂的吸湿性要优于现有技术的痫愈胶囊,崩解时限变化小,没有出现胶囊内容物吸湿和积聚等问题。因此,本发明提供的胶囊剂质量更稳定。
经过大生产验证,本发明提供的所述药物组合物及胶囊剂及制备方法,在填充胶囊过程中调机时间短,每批药粉的调机时间由原来的20~30分钟缩短为10~15分钟,且物料流动均匀流畅,粘附粉冲杆情况明显改善。人员工时、机器工时均较现有技术的工艺有所减少:填充一批物料(约420kg)由原工艺的10~12小时缩短为约8小时。填充过程稳定,填充后的胶囊装量差异范围缩小,由原工艺的±8%缩小为±5%。因此,本发明提供的药物组合物的处方及胶囊剂的制备方法不仅解决了现有技术中存在的制剂的困难,大大节约了生产成本,提高了生产效率,而且胶囊剂的稳定性均优于现有技术的痫愈胶囊剂;其它各项检查指标的波动均小于现有技术的痫愈胶囊。
Claims (6)
1.一种用于治疗癫痫抽搐、小儿惊风、面肌痉挛的药物组合物,由药材提取物和辅料组成;所述辅料为碳酸钙和磷酸氢钙,碳酸钙和磷酸氢钙的重量比为1:1,以所述药材提取物的重量为基准,所述辅料的重量百分比为10%;所述药材提取物由如下中药材经过提取制备得到:
黄芪140重量份、党参140重量份、丹参140重量份、柴胡70重量份、酸枣仁105重量份、远志70重量份、天麻105重量份、钩藤105重量份、石菖蒲70重量份、胆南星70重量份、当归140重量份、僵蚕105重量份、六神曲70重量份、郁金70重量份、甘草70重量份、制白附子35重量份。
2.根据权利要求1所述的药物组合物,其特征在于,所述药材提物通过如下方法制备:
按照重量份准备各味药材;僵蚕、六神曲粉碎成细粉,过80~100目筛,备用;其余十四味药材加水煎煮三次,第一次加水10倍量煎煮2小时,第二次加水8倍量煎煮次1.5小时,第三次加水6倍量煎煮1小时,合并煎液,滤过,滤液减压浓缩至在60℃下相对密度为1.36的稠膏,加入所述细粉,混合均匀,干燥,即得。
3.根据权利要求1或2所述的药物组合物,其特征在于,所述药物组合物为胶囊剂,胶囊内容物为所述药材提取物和所述辅料。
4.根据权利要求3所述的药物组合物的制备方法,包括如下步骤:
I. 将所述药材提取物粉碎,过80~100目筛,得到提取物细粉,备用;
II.将所述辅料粉碎、混合均匀;然后与步骤I得到的提取物细粉混合均匀;
III. 向步骤II得到的混合细粉中加入适量乙醇,制粒,干燥,装胶囊,即得。
5.根据权利要求4所述的制备方法,其特征在于,所述乙醇为体积百分比浓度80%~85%的乙醇水溶液。
6.一种胶囊剂,根据权利要求4或5所述的制备方法制备得到。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810382701.4A CN108420994B (zh) | 2018-04-26 | 2018-04-26 | 一种用于治疗癫痫抽搐、小儿惊风、面肌痉挛的药物组合物及其制备方法 |
PCT/CN2019/082398 WO2019205959A1 (zh) | 2018-04-26 | 2019-04-12 | 一种用于治疗癫痫抽搐、小儿惊风、面肌痉挛的药物组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810382701.4A CN108420994B (zh) | 2018-04-26 | 2018-04-26 | 一种用于治疗癫痫抽搐、小儿惊风、面肌痉挛的药物组合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108420994A CN108420994A (zh) | 2018-08-21 |
CN108420994B true CN108420994B (zh) | 2021-01-08 |
Family
ID=63161904
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810382701.4A Active CN108420994B (zh) | 2018-04-26 | 2018-04-26 | 一种用于治疗癫痫抽搐、小儿惊风、面肌痉挛的药物组合物及其制备方法 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN108420994B (zh) |
WO (1) | WO2019205959A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108420994B (zh) * | 2018-04-26 | 2021-01-08 | 西安千禾药业股份有限公司 | 一种用于治疗癫痫抽搐、小儿惊风、面肌痉挛的药物组合物及其制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1785409A (zh) * | 2005-11-17 | 2006-06-14 | 西安千禾药业有限责任公司 | 一种治疗癫痫抽搐、小儿惊风、面肌痉挛的药物及其制备方法 |
CN104547882A (zh) * | 2013-10-16 | 2015-04-29 | 西安千禾药业有限责任公司 | 一种治疗癫痫抽搐、小儿惊风、面肌痉挛的药物组合物痫愈的制备方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1857694A (zh) * | 2006-04-13 | 2006-11-08 | 贵州信邦制药股份有限公司 | 一种痫愈片中药复方制剂及其制备方法 |
CN103033587A (zh) * | 2011-09-30 | 2013-04-10 | 西安千禾药业有限责任公司 | 一种用于治疗癫痫抽搐、小儿惊风、面肌痉挛的药物的检测方法 |
CN108420994B (zh) * | 2018-04-26 | 2021-01-08 | 西安千禾药业股份有限公司 | 一种用于治疗癫痫抽搐、小儿惊风、面肌痉挛的药物组合物及其制备方法 |
-
2018
- 2018-04-26 CN CN201810382701.4A patent/CN108420994B/zh active Active
-
2019
- 2019-04-12 WO PCT/CN2019/082398 patent/WO2019205959A1/zh active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1785409A (zh) * | 2005-11-17 | 2006-06-14 | 西安千禾药业有限责任公司 | 一种治疗癫痫抽搐、小儿惊风、面肌痉挛的药物及其制备方法 |
CN104547882A (zh) * | 2013-10-16 | 2015-04-29 | 西安千禾药业有限责任公司 | 一种治疗癫痫抽搐、小儿惊风、面肌痉挛的药物组合物痫愈的制备方法 |
Non-Patent Citations (2)
Title |
---|
防潮辅料在中药固体制剂中的应用研究;何倩灵;《中国优秀博硕士学位论文全文数据库(硕士)工程科技辑》;20111115(第11期);第B016-119 页,尤其是摘要,第二、三部分小结 * |
黄河滩枣大枣多糖胶囊的制备及其质量考察;赵忠熙;《中国生化药物杂志》;20141231;第34卷(第8期);第162-166,169页 * |
Also Published As
Publication number | Publication date |
---|---|
WO2019205959A1 (zh) | 2019-10-31 |
CN108420994A (zh) | 2018-08-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1899361B (zh) | 贞芪药物组合及其制备 | |
KR102123972B1 (ko) | 두통을 치료하기 위한 약학적 조성물 및 그의 제조방법 | |
CN101850066A (zh) | 中药组合物颗粒剂及其制备方法 | |
CN113599363B (zh) | 一种心脉通胶囊的制备方法 | |
CN100534456C (zh) | 一种远志提取物及其制备方法和用途 | |
CN101732427A (zh) | 预防和/或治疗抑郁症和更年期综合症的药物组合物 | |
CN100525809C (zh) | 由黄芪、红景天和菝葜制成的药物组合物及其制备方法 | |
CN108420994B (zh) | 一种用于治疗癫痫抽搐、小儿惊风、面肌痉挛的药物组合物及其制备方法 | |
CN102362916A (zh) | 保肝中药复方提取物及其制备方法 | |
CN103393786A (zh) | 治疗哮喘病的药物及其制备方法 | |
CN106466396B (zh) | 一种妇科调经缓释滴丸及其制备方法 | |
CN105168612A (zh) | 一种治疗仔猪腹泻的药物及其制法与检测方法及用途 | |
CN102188592A (zh) | 一种治疗肿瘤化疗后血小板减少的药物及其制备方法 | |
CN102233089B (zh) | 一种用于更年期综合症的中药组合物及其制备方法 | |
CN101708307A (zh) | 一种用于治疗乳腺增生的药物及其制法 | |
CN107496578B (zh) | 治疗慢性咳喘的中药组合物及其制备方法与应用 | |
CN101693052B (zh) | 一种紫灯微丸及其制备方法 | |
CN100546634C (zh) | 一种治疗慢性肾间质纤维化的药物组合物及其制备方法 | |
CN115671055B (zh) | 一种中药颗粒制剂的制备方法及中药颗粒制剂 | |
CN109528825A (zh) | 一种具有活血化瘀和调经止痛功效的南丹参配方颗粒及其制备方法 | |
CN114767760B (zh) | 一种具有保肝作用的组合物 | |
CN103919795B (zh) | 一种含有三七素和三七皂苷r1药物组合物及其制剂 | |
CN106267122A (zh) | 一种栝楼桂枝滴丸及其质量检测方法 | |
CN103768494B (zh) | 一种治疗偏头痛的药物组合物及其制备方法和应用 | |
CN108030823A (zh) | 一种治疗鼻炎的中药 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |